Project description
The Czech Republic establishes the Pharma Centre of Excellence in Advanced Technology
Nucleic acids including DNA and RNA have shown exciting potential for the treatment of many diseases, not to mention their use in vaccines as demonstrated during the COVID-19 pandemic. Directed transport to specific tissues and cells remains a challenge. The Faculty of Pharmacy at Masaryk University in the Czech Republic is in an excellent position to tackle this challenge. The EU-funded ExcellPharmTech project will recruit a European Research Area Chair to establish the Pharma Centre of Excellence in Advanced Technology, intensifying research and development to enable the targeted delivery of nucleic acids to target cells and develop strategic partnerships for faster translation of the advanced drugs into clinics.
Objective
Masaryk University (MU) is the second-largest university in the Czech Republic located in Brno. Thanks to the ESIF funding, MU was able to acquire top research infrastructure attracting talented researchers who gradually built the position of the MU as the top regional hub for education, research, and innovation.
To further exploit this potential, the management structures and processes of the university must thoroughly implement the European Research Area (ERA) Priorities. As an outstanding researcher/innovator can have a decisive and positive impact on the culture and performance of any institution, MU will recruit a world-class research manager as an ERA Chair for its newly-established Faculty of Pharmacy.
The Faculty of Pharmacy (MUNI Pharm) is, besides others, focused on the development of advanced drug formulations and molecular biology techniques. The ERA Chair will intensify the research and development of advanced drug formulation and nanotechnologies to open new opportunities to intensify MUNI Pharm research capacities in the field of pharmacy and develop strategic partnerships with the application sphere and public sector for faster translation of the advanced drugs into clinics.
The recruitment of leading scientist will enforce the connection of the MUNI Pharm to research structures of MU, and the ERA Chair will make a bridge in the formation of unique education and research facility at one place titled MUNI BioPharma Hub, supported from National Recovery Plan (part of RRF Recovery and Resilience Facility, NextGeneration EU).
To solve the targeted delivery and transportation of nucleic acids into target cell environment, the MUNI Pharm will establish an interdisciplinary center of excellence (Pharma Center of Excellence in Advanced Technology) with prof. David Oupick as its leader. The creation of an international ERA Chair team will ensure a successful establishment of the center combining excellent research, high level education and top innovations.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.4.1 - Widening participation and spreading excellence
MAIN PROGRAMME
See all projects funded under this programme -
HORIZON.4.1.3 - ERA-Chairs
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-CSA - HORIZON Coordination and Support Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-WIDERA-2022-TALENTS-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
601 77 Brno
Czechia
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.